secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-07-18T23:59:59+00:00
Accession:  0001104659-25-068804
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute fully enrolls Phase 3 sunRIZE study of ersodetug; topline data expected by end of 2025
--------------------------------------------------------------------------------

- 63 participants enrolled (8 open-label infants, 55 double-blind); DMC recommended continuing with original sample size after interim analysis.
- Baseline hypoglycemia burden severe: mean 15 events/week (SMBG), 19% time <70 mg/dL (CGM); 51% hospitalized in past year.
- 76% of participants have kATP channel mutations (typically diazoxide non-responsive); 19% on 2+ medical therapies, 40% on enteral feeding.
- 29% experienced severe hypoglycemia with loss of consciousness requiring emergency intervention in past year.
- Topline safety and efficacy results from pivotal 24-week treatment period anticipated by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925068804/0001104659-25-068804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925068804/tm2521194d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-068804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer